Sugi Predict

Sugi Predict / Compounds / SCHEMBL147683

SCHEMBL147683

SCHEMBL147683

Cc1cc(C)c(C(N)=O)c(N)n1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 2/20 0.67
▸ CYP1A2 P05177 3/20 0.53
▸ MEN1 O00255 3/20 0.49
▸ LMNA P02545 3/20 0.49
▸ KMT2A Q03164 3/20 0.49
▸ ALDH1A1 P00352 3/20 0.48
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ MAPK1 P28482 1/20 0.48
▸ KDM4E B2RXH2 3/20 0.48
▸ IKBKB O14920 1/20 0.46
▸ CHUK O15111 1/20 0.46
▸ PRKACA P17612 1/20 0.46
▸ PRKACG P22612 1/20 0.46
▸ PRKACB P22694 1/20 0.46
▸ LIMK1 P53667 1/20 0.46
▸ BTK Q06187 1/20 0.46
▸ TP53 P04637 1/20 0.46
▸ BLM P54132 1/20 0.46
▸ HPGD P15428 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31295740 1.00 POLB (0.67) POLBCYP1A2MEN1LMNAKMT2A
SCHEMBL11118906 0.84 POLB (0.52) POLBCYP1A2MEN1LMNAKMT2A
SCHEMBL3986248 0.84 ALDH1A1 (0.63) POLBCYP1A2MEN1LMNAKMT2A
SCHEMBL14385079 0.82 POLB (0.50) POLBCYP1A2MEN1LMNAKMT2A
Hydrochloric Acid SCHEMBL920573 0.82 ALDH1A1 (0.61) POLBCYP1A2MEN1LMNAKMT2A
SCHEMBL14353515 0.82 POLB (0.69) POLBCYP1A2MEN1LMNAKMT2A
SCHEMBL18742213 0.81 POLB (0.58) POLBCYP1A2MEN1LMNAKMT2A
SCHEMBL27803829 0.80 POLB (1.00) POLBCYP1A2MEN1LMNAKMT2A
SCHEMBL10415523 0.79 KDM4E (0.53) POLBMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL11807266 0.79 KDM4E (0.50) POLBCYP1A2MEN1LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12037324-B2 Biarylmethyl heterocycles BRISTOL-MYERS SQUIBB COMPANY (US) 2024-07-16 — — US disclosed
US-12037324-B2 Biarylmethyl heterocycles BRISTOL-MYERS SQUIBB COMPANY (US) 2024-07-16 — — US disclosed
US-12037324-B2 Biarylmethyl heterocycles BRISTOL-MYERS SQUIBB COMPANY (US) 2024-07-16 — — US disclosed
EP-3478672-B1 BIARYLMETHYL HETEROCYCLES UNIV MONTREAL (CA) 2024-04-10 — — EP disclosed
CN-107252429-B Novel anti-inflammatory agent 雷斯韦洛吉克斯公司 2023-06-16 — — CN disclosed
US-20230045357-A1 BIARYLMETHYL HETEROCYCLES Université de Montréal (CA) 2023-02-09 — — US disclosed
US-20230045357-A1 BIARYLMETHYL HETEROCYCLES Université de Montréal (CA) 2023-02-09 — — US disclosed
US-11407733-B2 Biarylmethyl heterocycles BRISTOL-MYERS SQUIBB COMPANY (US) 2022-08-09 — — US disclosed
EP-3431086-B1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP (CA) 2020-06-17 — — EP disclosed
US-20200129512-A1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2020-04-30 — — US disclosed
US-20130281398-A1 TREATMENT OF DISEASES BY EPIGENETIC REGULATION RVX THERAPEUTICS INC. (CA) 2013-10-24 — — US disclosed
US-20120059002-A1 NOVEL ANTI-INFLAMMATORY AGENTS HEPALINK (HONG KONG) LIMITED (HK) 2012-03-08 — — US disclosed
EP-2421533-A1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2012-02-29 — — EP disclosed
WO-2010123975-A1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2010-10-28 — — WO disclosed
EP-1973886-A2 PROKINETICIN 1 RECEPTOR ANTAGONISTS Janssen Pharmaceutica, N.V. (BE) 2008-10-01 — — EP disclosed
WO-2007079163-A2 PROKINETICIN 1 RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-12 — — WO disclosed
US-5424432-A Chemical condensation, cyclization, aromatization; for synthesizing Angiotensin II receptor antagonists MERCK & CO., INC. (US) 1995-06-13 — — US disclosed
US-3966453-A Herbicidal 2-halo-4-trifluoromethyl-4'-cyanophenyl-ethers ISHIHARA SANGYO KAISHA LTD. (JA) 1976-06-29 — — US disclosed
US-3962264-A AMMONIA, TETRA-ALKOXY-PROPANE, MALONONITRILE PFIZER INC. (US) 1976-06-08 — — US disclosed
US-3950160-A INHIBITING THE GROWTH OF WEEDS WITH 2-SUBSTITUTED PYRDIDOPYIMIDINES AND SALTS THEREOF PFIZER INC. (US) 1976-04-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11407733-B2 Biarylmethyl heterocycles ARRB1, ADRB2, ADRB1 POLB 2720/4885CYP1A2 386/4885MEN1 4154/4885
US-20120059002-A1 NOVEL ANTI-INFLAMMATORY AGENTS VCAM1, ICAM1, IL6 POLB 3635/4885CYP1A2 2072/4885MEN1 1990/4885
US-20130281398-A1 TREATMENT OF DISEASES BY EPIGENETIC REGULATION PHKB, BAZ2A, EP300 POLB 282/4885CYP1A2 4765/4885MEN1 4236/4885
US-12037324-B2 Biarylmethyl heterocycles ARRB1, ADRB2, ADRB1 POLB 2720/4885CYP1A2 386/4885MEN1 4154/4885
US-20230045357-A1 BIARYLMETHYL HETEROCYCLES ARRB1, ADRB2, ADRB1 POLB 2720/4885CYP1A2 386/4885MEN1 4154/4885
US-20200129512-A1 NOVEL ANTI-INFLAMMATORY AGENTS VCAM1, ICAM1, IL6 POLB 3635/4885CYP1A2 2072/4885MEN1 1990/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.